A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Recruiting now · Phase 2
Conditions studied: Malignant Solid Tumors
In brief
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection combined with other antitumor drugs in patients with malignant solid tumors.
Key facts
- Study ID
- NCT07028281
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- People needed
- 120
- Starts
- 2025-07-08
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-03-03
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject has provided informed consent prior to initiation of any study-procedures
- Age from 18 to 75 years old at the time of signing the informed consent
- Histologically or cytologically confirmed solid tumors
- At least one measurable lesion was identified per RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Has a life expectancy of at least 3 months.
- Adequate organ function
- Subjects of both genders of child-bearing potential were required to use highly effective contraception from the time they provided written informed consent until 8 months after the last dose of the trial drug
You may not qualify if…
- Subjects with active central nervous system (CNS) metastasis.
- Subjects with a history of malignant tumors within 5 years prior to the first dose
- Subjects with uncontrolled cancer pain.
- Subjects with severe cardiovascular disease.
- Subjects with clinically significant hemorrhage
- Subjects with uncontrolled pleural effusion, peritoneal effusion and pericardial effusion
- Subjects highly suspected of interstitial lung disease
- Subjects with serious infection within 4 weeks prior to the first dose
- Known history of human immunodeficiency virus (HIV)，active hepatitis B virus or hepatitis C virus infection.
- The adverse events of previous antineoplastic therapy did not recover to NCI-CTCAE≤ grade 1
- Subjects who received anti-cancer treatment within 4 weeks prior to the first dose
- Subjects who received major surgery within 4 weeks prior to the first dose
- Subjects who plan to receive or have received live vaccines within 28 days prior to the first dose.
- Female subjects who were pregnant, lactating, or planned to become pregnant during the study period
- Known allergic to any component of investigational drugs
- Alcohol abuse, drug abuse, other serious medical conditions (including mental illness) requiring combined treatment, and other conditions that may affect subject safety or data collection.
- Based on the investigator's judgment, subjects with other conditions that may affect study results, interfere with study procedures,
Where it is running
- Affiliated Cancer Hospital of Shandong First Medical University — Jinan, Shandong, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.